Trial Profile
A Phase I Single Center Study to Evalute the Safety, Tolerability and Pharmacokinetics of Intravenous IdeS After Administration of Single Ascending Doses in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Mar 2019
Price :
$35
*
At a glance
- Drugs Imlifidase (Primary)
- Indications Transplant rejection
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors Hansa Biopharma AB; Hansa Medical AB
- 16 Jul 2015 According to Hansa Medical AB media release, results have been published in PLOS ONE.
- 16 Jul 2015 Results published in Hansa Medical AB media release.
- 18 Feb 2015 Results published in Hansa Medical AB media release.